Research Article
HBV-DNA Load-Related Peritumoral Inflammation and ALBI Scores Predict HBV Associated Hepatocellular Carcinoma Prognosis after Curative Resection
Table 1
Clinical backgrounds of all patients and comparisons between the training and validation cohorts.
| | Characteristics | Total | Training cohort | Internal validation cohort | External validation cohort | P-value | | n=652 | n=342 | n=124 | n=186 |
| | Age, yr, median, (range) | 52.5 (18.0-77.0) | 52.5 (18.0-75.0) | 51.5 (21.0-77.0) | 53.0 (18.0-75.0) | 0.293 | | Gender (Female/Male) | 95/557 (14.6%/85.4%) | 49/293 (14.3%/85.7%) | 19/105 (15.3%/84.7%) | 27/159 (14.5%/85.5%) | 0.964 | | Cirrhosis (yes/no) | 567/85 (87.0%/13%) | 301/41(88.0%/12.0%) | 102/22(82.3%/17.7%) | 164/22 (88.2%/11.8%) | 0.249 | | ALT U/L, median (range) | 40.0 (8.0-912.0) | 39.0 (9.0-912.0) | 37.5 (10.0-297.0) | 41.5 (8.0-835.0) | 0.369 | | AST, U/L, median (range) | 36.5 (7.0-527.0) | 36.0 (7.0-523.0) | 40.0 (12.0-205.0) | 36.0 (11.0-527.0) | 0.587 | | GGT, U/L, median (range) | 56.5 (7.0-624.0) | 55.0 (8.0-583.0) | 57.0 (9.0-624.0) | 56.5 (7.0-388.0) | 0.163 | | ALB, g/L, median (range) | 43.0 (28.0-59.0) | 43.0 (30.0-57.0) | 42.5 (28.0-59.0) | 43.0 (33.0-55.0) | 0.276 | | TBIL, μmol/L, median (range) | 13.8 (2.6-135.5) | 13.7 (4.6-135.5) | 13.9 (2.6-48.9) | 13.1 (4.7-95.3) | 0.258 | | Child-Pugh grade (A/B) | 650/2 (99.7%/0.3%)) | 340/2 (99.4%/0.6%) | 124/0 (100%/0) | 186/0 (100%/0) | 0.403 | | HBV-DNA loads | 207/445 (41.7%/58.3%) | 138/204 (40.4%/59.6%) | 26/98 (21.0%/79.0%) | 43/143 (23.1%/76.9%) | <0.001 | | (≤104/>104 copies/ml) | | Antiviral therapy (yes/no) | 98/554 (15.0%/85%) | 53/289 (15.5%/84.5%) | 20/104 16.1%/83.9%) | 25/161 (13.4%/86.6%) | 0.218 | | HBV-ALBI (I/II/III/IV) | 266/332/53/101 | 106/171/32/33 (31.0%/50.0%/9.4%/9.6%) | 14/56/13/41 | 46/105/8/27 | <0.001 | | (40.8%/50.9%/8.1%/15.5%) | (11.3%/45.2%/10.5%/33.0%) | (24.7%/56.5%/4.3%/14.5%) | | HBV-PIS (I/II/III/IV) | 105/219/102/226 | 62/88/76/116 (18.1%/25.7%/22.2%/34.0%) | 16/43/11/54 | 27/88/15/56 | <0.001 | | (16.1%/33.6%/15.6%/34.7%) | (12.9%/34.7%8.9%/43.5%%) | (14.5%/47.3%/8.1%/30.1%) | | AFP, ng/ml, (≤20/>20) | 265/387 (40.6%/59.4%) | 136/206(39.8%/60.1%) | 50/74(40.3%/59.7%) | 79/107 (42.5%/57.5%) | 0.798 | | Platelet, 109/L, median (range) | 138.0 (10.0-417.0) | 137.0 (25.0-417.0) | 137.5 (10.0-331.0) | 145.0 (46.0-333.0) | 0.139 | | HBsAg (Positive/Negative) | 538/114 (82.5%/17.5%)) | 285/57 (83.3%/16.7%) | 100/24 (80.6%/19.4%) | 153/33 (82.3%/17.7%) | 0.792 | | Tumor number (single/multiple) | 578/74 (88.7%/11.3%) | 301/41 (88.0%/12.0%) | 113/11 (91.1%/8.9%) | 164/22 (88.2%/11.8%) | 0.626 | | Microvascular invasion (yes/no) | 184/468 (28.2%/71.8%)) | 88/254 (25.7%/74.3%) | 35/89 (28.2%/71.8%) | 51/135 (27.4%/72.6%) | 0.152 | | Tumor capsule(complete/Inomplete) | 358/294 (54.9%/45.1%) | 188/154 (55.0%/45.0%) | 70/54 (56.5%/43.5%) | 100/86 (53.8%/46.2%) | 0.089 | | Tumor size, cm (≤3/>3) | 225/427 (34.5%/65.5%) | 123/219 (36.0%/64.0%) | 35/89 (28.2%/71.8%) | 67/119 (36.0%/64.0%) | 0.123 | | AJCC stage (I-II/IIIA) | 489/163 (75.0%/25.0%) | 268/74 (78.4%/21.6%) | 91/33 (73.4%/26.6%) | 130/56 (69.9%/30.1%) | 0.085 | | BCLC stage (0-A/B-C) | 418/234 (66.3%/33.7%) | 238/104 (69.6%/30.4%) | 83/41 (66.9%/33.1%) | 97/89 (52.2%/47.8%) | <0.001 |
|
|
ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase; ALB: Albumin; TBIL: total bilirubin; HBV-ALBI: hepatitis B virus load related ALBI score; HBV-PIS: hepatitis B virus load related peritumoral inflammatory score; AFP: alpha fetoprotein; HBsAg: hepatitis B virus surface antigen; AJCC: American Joint Committee on Cancer; BCLC: Barcelona Clinic Liver Cancer.
|
